Related Experiment Videos
The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia
1Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0366, USA.
Insights
New research reveals how hyperlipidemia and the renin-angiotensin system contribute to atherosclerosis. Angiotensin II worsens endothelial dysfunction, but angiotensin-converting enzyme (ACE) inhibitors may offer protection against heart attack.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Biochemistry
Background:
- Hyperlipidemia and renin-angiotensin system activation are linked to atherosclerotic disease.
- Endothelial dysfunction in atherosclerosis affects vasomotor tone, platelet activity, and inflammation.
- Angiotensin II exacerbates endothelial dysfunction by altering LDL binding and increasing uptake.
Purpose of the Study:
- To explore the interaction between hyperlipidemia, renin-angiotensin system activation, and atherosclerosis.
- To investigate the role of Angiotensin II in endothelial dysfunction.
- To evaluate the potential therapeutic benefits of ACE inhibitors and statins.
Main Methods:
- Review of current evidence on the mechanisms of atherosclerosis.
- Analysis of the effects of Angiotensin II on endothelial function.
- Discussion of the therapeutic implications of ACE inhibitors and statins.
Main Results:
- Angiotensin II impairs nitric oxide production and promotes oxidative stress, worsening endothelial dysfunction.
- ACE inhibitors may counteract the adverse effects of Angiotensin II, potentially reducing myocardial infarction risk.
- Statins are known to improve endothelial function and reduce ischemic events.
Conclusions:
- ACE inhibitors show promise in correcting endothelial dysfunction and may benefit patients with atherosclerosis.
- Combination therapy with ACE inhibitors and statins might offer synergistic effects in managing atherosclerosis.
- Further research is needed to establish the role of ACE inhibitors in preventing coronary artery disease without left ventricular dysfunction.
Abstract:
New evidence suggests an interaction between hyperlipidemia, activation of the renin-angiotensin system, and atherosclerotic disease. In patients with atherosclerosis and hyperlipidemia, coronary endothelial dysfunction is usually diffuse and affects vasomotor tone, platelet activity, thrombosis, fibrinolysis, and regulation of inflammatory cells. Angiotensin II, an important oxidant, alters the binding of low-density-lipoprotein (LDL) cholesterol to its receptors and increases endothelial uptake of LDL. Endothelial dysfunction is worsened by the suppression of nitric oxide production and/or release via angiotensin II-associated degradation of bradykinin and oxygen free radical production, resulting in inadequate vasorelaxation. Therapy with angiotensin-converting enzyme (ACE) inhibitors appears to eliminate these untoward effects and may ameliorate the tendency for myocardial infarction associated with elevated plasma levels of angiotensin II. Although the role of ACE inhibitors in the prevention and/or treatment of coronary artery disease in patients without left ventricular dysfunction remains to be established, the capacity of ACE inhibition to correct endothelial dysfunction offers promise. The ability of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to improve endothelial function, prevent the progression of coronary atherosclerosis, reduce the incidence of ischemic events, and improve survival is well known. Potentially, ACE inhibitors may have an additive or synergistic effect on the development of atherosclerosis and the clinical consequences of this disease when used in combination therapy with lipid-lowering strategies.